On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON ...

Editas Medicine (EDIT) has been downgraded to market perform from outperform by Raymond James due in part to extended ...

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with ...

Raymond James downgraded Editas Medicine (EDIT) to Market Perform from Outperform without a price target The firm cites the company’s ...

Beam Therapeutics Inc. disclosed that one patient died in the phase I/II trial testing BEAM-101 in sickle cell disease (SCD), though the case of respiratory failure was determined by the investigator ...

Acute myeloid leukemia was the most common reason for a transplant. Group 1 more commonly received myeloablative preparative ...

第66届美国血液学会（ASH）将于2024年12月7～10日在美国圣迭戈（San Diego）盛大召开。作为全球血液学领域规模最大、涵盖最全面的国际学术盛会之一，每年吸引着成千上万名来自世界各地的专家学者，分享最前沿的血液学进展和突破性临床数据。日前 ...

Older patients with MDS often receive reduced intensity conditioning regimens. These regimens tend to be less aggressive than traditional myeloablative therapies. The specific regimens mentioned ...

A few days before Casgevy is infused, patients undergo myeloablative chemo to wipe out their bone marrow, removing unhealthy blood stem cells and making room for the new, edited versions.

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that ...